How NuVasive is approaching headwinds ahead of merger

Spinal Tech

NuVasive's CEO Chris Barry remains confident the spine company will meet its planned merger with Globus Medical on schedule, he said in an Aug. 2 earnings call.

Shareholders with both companies approved the deal in April. But now, the Federal Trade Commission is weighing a potential antitrust lawsuit that could challenge that.

Mr. Barry described current affairs as a "dynamic situation."

"The team is working very hard to make sure that we're getting everything that's asked of us, and I think we've done so effectively up to this point," Mr. Barry said, as transcribed by Seeking Alpha. "As far as the range of outcomes, clearly, the FTC reviewed the information that we provided and ultimately came back to us at some point."
He also addressed any speculation that the more than $3 billion deal is anti-competitive.

"I'm confident in the Q3 time frame because … I don't believe this is anti-competitive," he said. "I think there's lots of competitors. I think there's a low bar of entry for competitors coming into this space. And for all those reasons, the combination of us and Globus, I think actually is much better for patients. It actually opens up the opportunity to further innovate and ultimately change patient outcomes, which is our focus as a company."

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers